CAPTRUST Financial Advisors
VTGN icon

CAPTRUST Financial Advisors’s VistaGen Therapeutics VTGN Stock Holding History

CAPTRUST Financial Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,640
Closed -$13.6K – 2596
2023
Q1 		$13.6K Buy
+3,640
New +$19.1K ﹤0.01% 2262
2022
Q4 		– Sell
-3,500
Closed -$16K – 2194
2022
Q3 		$16K Buy
3,500
+3,333
+1,996% +$33K ﹤0.01% 2021
2022
Q2 		$4K Hold
167
– – ﹤0.01% 4226
2022
Q1 		$6K Sell
167
-275
-62% -$12K ﹤0.01% 4091
2021
Q4 		$26K Buy
442
+264
+148% +$17.2K ﹤0.01% 3123
2021
Q3 		$15K Buy
178
+11
+7% +$956 ﹤0.01% 3366
2021
Q2 		$16K Buy
+167
New +$12.4K ﹤0.01% 3280

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAPTRUST Financial Advisors's VTGN Position: Q2 2023 in Review

CAPTRUST Financial Advisors sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 3,640 shares — an estimated $13.6K sold.

CAPTRUST Financial Advisors first reported a position in VTGN in Q2 2021 and held it in 7 quarters. The position peaked at $26K in Q4 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • CAPTRUST Financial Advisors reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 3,640 VistaGen Therapeutics shares in Q2 2023, an estimated $13.6K.
  • CAPTRUST Financial Advisors first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 7 quarters.
  • CAPTRUST Financial Advisors's VistaGen Therapeutics position peaked at $26K in Q4 2021.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2023, filed 15 Aug 2023.